SK Bioscience FY 2025 Annual Report
Beta

Filed: March 13, 2026· period ending December 31, 2025DART

SK Bioscience annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 13, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).

SK Bioscience FY 2025 Annual Report Analysis

Business Overview

• 2025 sales KRW 651.4B with 71.5% from CDMO, vaccine development 28.5%
• June 2025 completion of pneumococcal vaccine production facility expansion at Andong L HOUSE

Management Discussion & Analysis

• Revenue KRW 651.4B (+143.5% YoY), operating loss KRW -123.5B (-10.8% deficit reduction), net loss KRW -56.2B (-12.1%)
• IDT Biologika acquisition in Q4 2024 drove revenue growth and operational improvement

Risk Factors

• Foreign exchange exposure hedged with currency forward contracts, contract amount KRW 21.99B, reducing FX risk impact on earnings
• Derivative liabilities KRW 105.3M at fiscal year-end, down from KRW 1.66B prior year, largest single quantified derivative liability

SK Bioscience FY 2025 Key Financial Metrics
DART

Total Assets

KRW 2.96T

▲ +3.9% YoY

Operating Cash Flow

KRW 102.5B

▲ +180.1% YoY

CapEx

KRW 183.1B

▲ +11.4% YoY

Source: KIFRS consolidated financial data from SK Bioscience annual report on DART. All figures in KRW.

Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding